The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from Business Wire

Teva to Report Fourth Quarter and Full Year 2012 Financial Results on February 7, 2013

Tuesday, January 22, 2013

Teva to Report Fourth Quarter and Full Year 2012 Financial Results on February 7, 201308:30 EST Tuesday, January 22, 2013 JERUSALEM (Business Wire) -- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it will release its fourth quarter and full year 2012 financial results on Thursday, February 7, 2013 at 7:00 a.m. EST. Teva will host a conference call and live webcast on the same day, at 8:00 a.m. EST to discuss its fourth quarter and full year 2012 results and overall business environment. A Question & Answer session will follow this discussion. In order to participate, please dial the following numbers (at least 10 minutes before the scheduled start time): United States and Canada 1-888-771-4371; International 1-847-585-4405; passcode: 34121499. A live webcast of the call will also be available on Teva's website at: www.tevapharm.com. Please log in at least 10 minutes prior to the conference call in order to download the applicable audio software. Following the conclusion of the call, a replay of the webcast will be available within 24 hours on the Company's website. The replay can also be accessed until February 14, 2013, at 11:59 p.m. ET by calling 1-888-843-7419 or 1-630-652-3042; passcode: 34121499#. About Teva Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of approximately 1,000 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 46,000 people around the world and reached $18.3 billion in net revenues in 2011. TevaIR:Kevin C. Mannix, 215-591-8912United StatesorJoseph Marczely, 267-468-4281United StatesorTomer Amitai, 972 (3) 926-7656IsraelorPR:Hadar Vismunski-Weinberg, 972 (3) 926-7687IsraelorDenise Bradley, 215-591-8974United States